[A22-98] Nivolumab (oesophageal carcinoma, combination with chemotherapy) – Addendum to Commission A22-54
Last updated 20.10.2022
Commission awarded on 06.09.2022 by the Federal Joint Committee (G-BA).
Adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%; first-line treatment; combination with fluoropyrimidine- and platinum-based combination chemotherapy
After addendum now indication of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.